ATP modulates poly(ADP-ribose) polymerase-1-facilitated topoisomerase I-linked DNA religation in the presence of camptothecin

Molecular Pharmacology

Volumn 73, Issue 6, 2008, Pages 1829-1837

  Park, Shin Young ^a,b   Leung, Chung Hang ^a,c   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Korea Institute of Toxicology   (South Korea)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CAMPTOTHECIN; CYTIDINE TRIPHOSPHATE; DNA; DNA TOPOISOMERASE; GUANOSINE TRIPHOSPHATE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NUCLEOTIDE DERIVATIVE; TOPOTECAN; URIDINE TRIPHOSPHATE;

ARTICLE; BINDING SITE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; ENZYME ACTIVITY; ENZYME REGULATION; GENE CONTROL; HYDROLYSIS; NUCLEIC ACID STRUCTURE; PRIORITY JOURNAL; PROTEIN INTERACTION;

ADENOSINE TRIPHOSPHATE; ANIMALS; CAMPTOTHECIN; CELL LINE; DNA; DNA TOPOISOMERASES, TYPE I; HUMANS; INSECTS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 44249121712     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.044438     Document Type: Article

References (49)

1. Ariumi Y, Masutani M, Copeland TD, Mimori T, Sugimura T, Shimotohno K, Ueda K, Hatanaka M, and Noda M (1999) Suppression of the poly(ADP-ribose) polymerase activity by DNA-dependent protein kinase in vitro. Oncogene 18:4616-4625.
2. Beidler DR, Chang JY, Zhou BS, and Cheng YC (1996) Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res 56:345-353.
3. +. FEBS J 272:4576-4589.
4. Bürkle A, Diefenbach J, Brabeck C, and Beneke S (2005) Ageing and PARP. Pharmacol Res 52:93-99.
5. Castora FJ and Kelly WG (1986) ATP inhibits nuclear and mitochondrial type I topoisomerases from human leukemia cells. Proc Natl Acad Sci U S A 83:1680-1684.
6. Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70:369-413.
7. Chatterjee S, Cheng MF, Trivedi D, Petzold SJ, and Berger NA (1989) Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deficient cell lines. Cancer Commun 1:389-394.
8. Chen BF and Castora FJ (1988) Mechanism of ATP inhibition of mammalian type I DNA topoisomerase: DNA binding, cleavage, and rejoining are insensitive to ATP. Biochemistry 27:4386-4391.
9. Chen HJ and Hwang J (1999) Binding of ATP to human DNA topoisomerase I resulting in an alteration of the conformation of the enzyme. Eur J Biochem 265:367-375.
10. Cimmino G, Pepe S, Laus G, Chianese M, Prece D, Penitente R, and Quesada P (2007) Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines. Pharmacol Res 55:49-56.
11. Ferro AM, Higgins NP, and Olivera BM (1983) Poly(ADP-ribosylation) of a DNA topoisomerase. J Biol Chem 258:6000-6003.
12. Fioravanti M and Yanagi M (2005) Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev CD000269.
13. Foglesong PD and Bauer WR (1984) Effects of ATP and inhibitory factors on the activity of vaccinia virus type I topoisomerase. J Virol 49:1-8.
14. Gajewski CD, Yang L, Schon EA, and Manfredi G (2003) New insights into the bioenergetics of mitochondrial disorders using intracellular ATP reporters. Mol Biol Cell 14:3628-3635.
15. Goto T, Laipis P, and Wang JC (1984) The purification and characterization of DNA topoisomerases I and II of the yeast Saccharomyces cerevisiae. J Biol Chem 259:10422-10429.
16. Hsiang YH, Lihou MG, and Liu LF (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082.
17. Ivana Scovassi A and Diederich M (2004) Modulation of poly(ADP-ribosylation) in apoptotic cells. Biochem Pharmacol 68:1041-1047.
18. Jiang LJ, Maret W, and Vallee BL (1998) The ATP-metallothionein complex. Proc Natl Acad Sci U S A 95:9146-9149.
19. Jongstra-Bilen J, Ittel ME, Niedergang C, Vosberg HP, and Mandel P (1983) DNA topoisomerase I from calf thymus is inhibited in vitro by poly(ADP-ribosylation). Eur J Biochem 136:391-396.
20. +-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell 119:803-814.
21. + into a nuclear signal. Genes Dev 19:1951-1967.
22. 2+, histones H1 and H3, and ATP. Biochemistry 43:210-216.
23. Liu LF, Desai SD, Li TK, Mao Y, Sun M, and Sim SP (2000) Mechanism of action of camptothecin. Ann N Y Acad Sci 922:1-10.
24. Liu SY, Hwang BD, Liu ZC, and Cheng YC (1989) Interaction of several nucleoside triphosphate analogues and 10-hydroxycamptothecin with human DNA topoisomerases. Cancer Res 49:1366-1370.
25. Lorence A and Nessler CL (2004) Camptothecin, over four decades of surprising findings. Phytochemistry 65:2735-2749.
26. Low RL and Holden JA (1985) Inhibition of HeLa cell DNA topoisomerase I by ATP and phosphate. Nucleic Acids Res 13:6999-7014.
27. McLennan AG (2000) Dinucleoside polyphosphates-friend or foe? Pharmacol Ther 87:73-89.
28. Meyer-Ficca ML, Meyer RG, Jacobson EL, and Jacobson MK (2005) Poly(ADP-ribose) polymerases: managing genome stability. Int J Biochem Cell Biol 37:920-926.
29. Miller DS and Horowitz SB (1986) Intracellular compartmentalization of adenosine triphosphate. J Biol Chem 261:13911-13915.
30. Oei SL, Keil C, and Ziegler M (2005) Poly(ADP-ribosylation) and genomic stability. Biochem Cell Biol 83:263-269.
31. Ogilvie A, Blasius R, Schulze-Lohoff E, and Sterzel RB (1996) Adenine dinucleotides: a novel class of signalling molecules. J Auton Pharmacol 16:325-328.
32. Park SY and Cheng YC (2005) Poly(ADP-ribose) polymerase-1 could facilitate the religation of topoisomerase I-linked DNA inhibited by camptothecin. Cancer Res 65:3894-3902.
33. Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6:789-802.
34. Pourquier P and Pommier Y (2001) Topoisomerase I-mediated DNA damage. Adv Cancer Res 80:189-216.
35. Rossi F, Labourier E, Forne T, Divita G, Derancourt J, Riou JF, Antoine E, Cathala G, Brunel C, and Tazi J (1996) Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature 381:80-82.
36. Rossi F, Labourier E, Gallouzi IE, Derancourt J, Allemand E, Divita G, and Tazi J (1998) The C-terminal domain but not the tyrosine 723 of human DNA topoisomerase I active site contributes to kinase activity. Nucleic Acids Res 26:2963-2970.
37. Rowe TC, Rusche JR, Brougham MJ, and Holloman WK (1981) Purification and properties of a topoisomerase from Ustilago maydis. J Biol Chem 256:10354-10361.
38. Sekiguchi J and Shuman S (1994) Stimulation of vaccinia topoisomerase I by nucleoside triphosphates. J Biol Chem 269:29760-29764.
39. Shaffer R and Traktman P (1987) Vaccinia virus encapsidates a novel topoisomerase with the properties of a eucaryotic type I enzyme. J Biol Chem 262:9309-9315.
40. Smith AJ, Meyer PR, Asthana D, Ashman MR, and Scott WA (2005) Intracellular substrates for the primer-unblocking reaction by human immunodeficiency virus type 1 reverse transcriptase: detection and quantitation in extracts from quiescent-and activated-lymphocyte subpopulations. Antimicrob Agents Chemother 49:1761-1769.
41. Sriram D, Yogeeswari P, Thirumurugan R, and Bal TR (2005) Camptothecin and its analogues: a review on their chemotherapeutic potential. Nat Prod Res 19:393-412.
42. Stewart L, Ireton GC, and Champoux JJ (1999) A functional linker in human topoisomerase I is required for maximum sensitivity to camptothecin in a DNA relaxation assay. J Biol Chem 274:32950-32960.
43. Stewart L, Ireton GC, Parker LH, Madden KR, and Champoux JJ (1996) Biochemical and biophysical analyses of recombinant forms of human topoisomerase I. J Biol Chem 271:7593-7601.
44. Strosznajder RP, Jesko H, and Zambrzycka A (2005) Poly(ADP-ribose) polymerase: the nuclear target in signal transduction and its role in brain ischemia-reperfusion injury. Mol Neurobiol 31:149-167.
45. Thomas CJ, Rahier NJ, and Hecht SM (2004) Camptothecin: current perspectives. Bioorg Med Chem 12:1585-1604.
46. Wang JC (1985) DNA topoisomerases. Annu Rev Biochem 54:665-697.
47. Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 65:635-692.
48. Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430-440.
49. Wu J and Liu LF (1997) Processing of topoisomerase I cleavable complexes into DNA damage by transcription. Nucleic Acids Res 25:4181-4186.